What’s in MyoKardia, Inc. (MYOK) After Today’s Big Increase?

March 14, 2018 - By Lynda A. Deweese

The stock of MyoKardia, Inc. (NASDAQ:MYOK) is a huge mover today! The stock increased 6.82% or $3.4 during the last trading session, reaching $53.25. About 726,743 shares traded or 71.06% up from the average. MyoKardia, Inc. (NASDAQ:MYOK) has risen 11.16% since March 14, 2017 and is uptrending. It has underperformed by 5.54% the S&P500.
The move comes after 7 months positive chart setup for the $1.91B company. It was reported on Mar, 14 by Barchart.com. We have $56.98 PT which if reached, will make NASDAQ:MYOK worth $133.91 million more.

Analysts await MyoKardia, Inc. (NASDAQ:MYOK) to report earnings on May, 8. They expect $-0.32 EPS, up 13.51 % or $0.05 from last year’s $-0.37 per share. After $-0.21 actual EPS reported by MyoKardia, Inc. for the previous quarter, Wall Street now forecasts 52.38 % negative EPS growth.

MyoKardia, Inc. (NASDAQ:MYOK) Ratings Coverage

Among 5 analysts covering MyoKardia (NASDAQ:MYOK), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. MyoKardia had 5 analyst reports since November 23, 2015 according to SRatingsIntel. The stock has “Outperform” rating by Wedbush on Monday, November 23. Cowen & Co initiated MyoKardia, Inc. (NASDAQ:MYOK) on Monday, November 23 with “Outperform” rating. Wells Fargo initiated the stock with “Outperform” rating in Friday, December 4 report. BMO Capital Markets initiated MyoKardia, Inc. (NASDAQ:MYOK) on Wednesday, July 20 with “Outperform” rating. The firm has “Outperform” rating given on Monday, November 23 by Credit Suisse.

More recent MyoKardia, Inc. (NASDAQ:MYOK) news were published by: Globenewswire.com which released: “MyoKardia Begins Patient Dosing in Phase 1b Clinical Study of MYK-491 in …” on February 14, 2018. Also Globenewswire.com published the news titled: “MyoKardia Reports Fourth Quarter and Full Year 2017 Financial Results” on March 08, 2018. Globenewswire.com‘s news article titled: “MyoKardia Announces Positive Results from Low-Dose Cohort of Phase 2 PIONEER …” with publication date: March 08, 2018 was also an interesting one.

MyoKardia, Inc., a clinical stage biopharmaceutical company, engages in discovering, developing, and commercializing therapies for the treatment of serious and neglected rare cardiovascular diseases. The company has market cap of $1.91 billion. The Company’s lead product candidate is MYK-461, an orally-administered small molecule that is in Phase II clinical trials designed to reduce excessive cardiac muscle contractility leading to hypertrophic cardiomyopathy . It currently has negative earnings. The firm also develops MYK-491, an orally-administered small molecule that treats genetic dilated cardiomyopathy (DCM) by restoring normal contractility in the diseased DCM heart.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.